早期子宫内膜癌腹腔细胞学阳性的预后与治疗:来自美国国家癌症数据库的匹配队列分析
该回顾性队列分析纳入2010-2013年美国国家癌症数据库16851例FIGO IA-II期子宫内膜癌女性,其中953例细胞学阳性。细胞学阳性与总生存下降相关(HR 1.85,95%CI 1.54-2.21,P<.001),辅助化疗与生存改善相关(HR 0.62,95%CI 0.40-0.95,P=.03)。
要点
- FIGO IA-II期子宫内膜癌中,腹腔细胞学阳性与总生存下降相关(HR 1.85,95%CI 1.54-2.21)。
- FIGO 1/2级子宫内膜样腺癌中,细胞学阳性的死亡风险相似(HR 1.85,95%CI 1.28-2.67)。
- 细胞学阳性者使用辅助化疗与生存改善相关(HR 0.62,95%CI 0.40-0.95,P=.03)。
核心结论
- 腹腔细胞学阳性与FIGO I/II期子宫内膜癌(包括低级别子宫内膜样癌)女性总生存下降相关。
- FIGO I/II期子宫内膜癌且细胞学阳性女性接受辅助化疗与生存改善相关。
研究设计与样本
- 观察性回顾性队列分析,使用2010-2013年美国国家癌症数据库,纳入有细胞学状态且为FIGO IA-II期的子宫内膜癌女性。
- 共纳入16851例女性,其中953例细胞学阳性。
- 进行整体队列和匹配队列生存分析,并对缺失数据进行插补和不插补分析。
- 对细胞学阳性女性按化疗暴露分组进行生存分析,采用多变量Cox比例风险回归校正可能混杂因素,并进行多种敏感性分析(包括结果对未测量混杂的稳健性)。
主要发现
- FIGO I/II期细胞学阳性女性4年总生存率为79.5%(范围76.2-83.0%),而细胞学阴性的IA、IB、II期分别为92.2%(范围91.5-92.9%)、83.3%(范围81.6-84.9%)、86.8%(范围85.1-88.5%)(P≤.001)。
- 细胞学阳性与生存下降相关(HR 1.85,95%CI 1.54-2.21,P<.001)。
- FIGO 1/2级子宫内膜样腺癌中,细胞学阳性相关的死亡风险相似(HR 1.85,95%CI 1.28-2.67,P<.001)。
- 细胞学阳性女性使用辅助化疗与生存改善相关(HR 0.62,95%CI 0.40-0.95,P=.03)。
临床怎么用
- 原文结论指出,FIGO I/II期子宫内膜癌且细胞学阳性女性接受辅助化疗与生存改善相关;作者未给出具体推荐等级。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While positive peritoneal cytology is no longer included among the endometrial cancer staging criteria, Federation International de Gynecologie et Obstetrique recommends continued collection of pelvic washings for cytology to produce additional data that may be used to determine the significance of positive cytology for prognosis and treatment of endometrial cancer. OBJECTIVES: The objectives of the study was to validate that positive cytology is a predictor of decreased survival in early endometrial cancer and to test whether adjuvant chemotherapy for positive cytology is associated with increased survival. STUDY DESIGN: We performed an observational retrospective cohort analysis of the 2010-2013 National Cancer Database including women with cytology status and Federation International de Gynecologie et Obstetrique stage IA-II endometrial cancer. Overall cohort and matched cohort survival analyses were performed with and without imputation of missing data. We also performed survival analyses of women with positive cytology grouped by chemotherapy exposure. Multivariable Cox proportional-hazards regressions were performed to adjust for possible confounders. A variety of sensitivity analyses, including robustness of results to possible unmeasured confounding, were reported. RESULTS: A total of 16,851 women including 953 with positive cytology were included. Four-year overall survival was 79.5% (range, 76.2-83.0%) for women with stage I/II with positive cytology vs 92.2% (range, 91.5-92.9%), 83.3% (range, 81.6-84.9%), and 86.8% (range, 85.1-88.5%) for stage IA, IB, and II with negative cytology, respectively (P ≤ .001). Positive cytology was associated with decreased survival (hazard ratio [95% confidence interval], 1.85 [range, 1.54-2.21], P < .001). For women with Federation International de Gynecologie et Obstetrique grade 1/2 endometrioid adenocarcinoma, the hazard of death associated with positive cytology was similar (hazard ratio [95% confidence interval], 1.85 [1.28-2.67], P < .001). Use of adjuvant chemotherapy by women with positive cytology was associated with increased survival (hazard ratio [95% confidence interval], 0.62 [0.40-0.95], P = .03). CONCLUSION: Positive peritoneal cytology was associated with decreased overall survival of women with Federation International de Gynecologie et Obstetrique stage I/II endometrial cancer, including low-grade endometrioid endometrial cancer. Treatment of women with stage I/II endometrial cancer and positive cytology with adjuvant chemotherapy was associated with increased survival.
引用
- Seagle BL, Alexander AL, Lantsman T, et al. Prognosis and treatment of positive peritoneal cytology in early endometrial cancer: matched cohort analyses from the National Cancer Database. Am J Obstet Gynecol. 2017. PMID: 29223598. doi:10.1016/j.ajog.2017.11.601
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。